Fyarro (Sirolimus Protein-Bound) Patent Expiration, LOE Window & CMS Spending
Fyarro (Sirolimus Protein-Bound) by Aadi Bioscience: FDA Orange Book LOE 2040-10-28, 4 AB generics, $1.5M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Aadi Bioscience |
| FDA Application & Pathway | N213312 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2040-10-28 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 4 |
| 2024 CMS Total Public Spend | $1.5M |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $1.5M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 24.7% 2-yr change) |